Regeneron cuts White House pricing deal, offers new gene therapy for free
The White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.
Cytiva Navigating cell therapy WP 4
Eli Lilly doubles down on in vivo with $7bn Kelonia buyout
The innovators working to make in vivo cell therapy a reality
Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease
Calls for change as access to cell and gene therapies in the Netherlands falls short
Nonprofit models support strategic boldness to develop gene therapies for rare diseases
Gene editing takes centre stage in FDA’s new rare disease approval pathway
Gilead acquires CAR-T specialist Arcellx for $7.8bn
